Journal
BIOSENSORS & BIOELECTRONICS
Volume 181, Issue -, Pages -Publisher
ELSEVIER ADVANCED TECHNOLOGY
DOI: 10.1016/j.bios.2021.113134
Keywords
COVID-19; SARS-CoV-2; Antibody; In vitro diagnostics; Nanopore
Categories
Funding
- COVID-19 Research Initiative of the University of South Carolina Office of the Vice President for Research
- Biomedical Engineering Program
- Department of Chemical Engineering of the University of South Carolina
- National Institute of Allergy and Infectious Diseases (NIAID) [K22AI136686]
- National Institute of General Medical Sciences (NIGMS) [P20GM103499]
- National Science Foundation (NSF) CAREER Award [2047503]
- Div Of Chem, Bioeng, Env, & Transp Sys
- Directorate For Engineering [2047503] Funding Source: National Science Foundation
Ask authors/readers for more resources
The article introduces a new serologic assay method utilizing DNA-assisted nanopore sensing for quantification of SARS-CoV-2 antibodies in human serum. This technology provides higher accuracy, larger dynamic range, and potential for automated testing compared to current clinically used point-of-care assays and ELISA assays.
The coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread into a global pandemic. Early and accurate diagnosis and quarantine remain the most effective mitigation strategy. Although reverse transcriptase polymerase chain reaction (RT-qPCR) is the gold standard for COVID-19 diagnosis, recent studies suggest that nucleic acids were undetectable in a significant number of cases with clinical features of COVID-19. Serologic assays that detect human antibodies to SARS-CoV-2 serve as a complementary method to diagnose these cases, as well as to identify asymptomatic cases and qualified convalescent serum donors. However, commercially available enzyme-linked immunosorbent assays (ELISA) are laborious and non-quantitative, while point-of-care assays suffer from low detection accuracy. To provide a serologic assay with high performance and portability for potential point-of-care applications, we developed DNA-assisted nanopore sensing for quantification of SARS-CoV-2 related antibodies in human serum. Different DNA structures were used as detection reporters for multiplex quantification of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against the nucleocapsid protein of SARS-CoV-2 in serum specimens from patients with conformed or suspected infection. Comparing to a clinically used point-of-care assay and an ELISA assay, our technology can reliably quantify SARS-CoV-2 antibodies with higher accuracy, large dynamic range, and potential for assay automation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available